The government announced today (18th) that the Secretary for Medical Services and Health has approved Fosun Pharma/German pharmaceutical company BioNTech's Fubitai in accordance with the Prevention and Control of Disease (Use of Vaccines) Regulation (Cap. 599K) ("Regulation") The original strain/Omicron mutant strain BA.4-5 bivalent vaccine (i.e. Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified)) is used for emergency in Hong Kong use.
According to the government, according to the information provided by the pharmaceutical factory, the first batch of Fubitai original strain/Omicron mutant strain BA.4-5 bivalent vaccine supplied to Hong Kong is expected to arrive in Hong Kong from Germany by the end of this month.
After the government receives the relevant vaccines and completes the necessary quality inspection procedures, it will provide the relevant vaccines to the public as soon as possible. Details will be announced later.
▼September 10, Mid-Autumn Festival, parents take their young children to get the new crown vaccine▼
+1
According to the Government, according to the "Regulation", the Secretary for Medical and Health Services may, after referring to the advice of the Advisory Committee on Vaccines for COVID-19 (the Advisory Committee), approve the use of the new crown vaccine in Hong Kong in emergency situations that meets the safety, efficacy and quality requirements For specified purposes, it basically refers to the COVID-19 vaccination program implemented by the government.
▼September 1, the first day of vaccination services provided by private clinics in Causeway Bay▼
+14
The Advisory Expert Committee has submitted a recommendation to the Secretary for Medical and Health Affairs, arguing that under the current epidemic situation, the use of Fubitai original strain/Omicron variant strain BA.4-5 bivalent vaccine as a booster is more effective in preventing COVID-19 than risk.
The Secretary for Medical and Health Services, after referring to the advice of the Advisory Expert Committee and considering the threat posed by the 2019 coronavirus disease to public health, considers that the accreditation is necessary and in the public interest, and has exercised the powers conferred by section 3 of the Regulation, Approved Fubitai original strain/Omicron mutant strain BA.4-5 bivalent vaccine for specified purposes in Hong Kong.
In order to ensure the continuous safety, effectiveness and quality assurance of the relevant vaccines, the Director of the Medical and Health Bureau has additional conditions for the above-mentioned accreditation, including requiring the applicant to continue to submit the latest clinical data of the vaccine, safety update reports, and quality certification documents for each batch of vaccines produced by the pharmaceutical factory Wait.
The government promotes the transitional vaccine pass, and it is expected that the new crown vaccine of Fubitai bivalent vaccine can be administered in December｜Society of Pharmacists: The BB version of Fubitai bivalent vaccine can be inoculated before Christmas in Hong Kong at the end of November Experts point out that the appointment rate is not ideal Worried about children failing to build a protective barrier, the BB version of Fubitai opened on the first day, dozens of parents took their children for injections, hoping to strengthen protection and facilitate travel abroad